Cross Country Healthcare (CCRN)
(Delayed Data from NSDQ)
$17.11 USD
-0.44 (-2.51%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $17.12 +0.01 (0.06%) 7:58 PM ET
4-Sell of 5 4
A Value A Growth F Momentum A VGM
Cross Country Healthcare (CCRN) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$18.83 | $22.00 | $16.00 | 7.29% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for Cross Country Healthcare comes to $18.83. The forecasts range from a low of $16.00 to a high of $22.00. The average price target represents an increase of 7.29% from the last closing price of $17.55.
Analyst Price Targets (6 )
Broker Rating
Cross Country Healthcare currently has an average brokerage recommendation (ABR) of 2.44 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by nine brokerage firms. The current ABR compares to an ABR of 2.44 a month ago based on nine recommendations.
Of the nine recommendations deriving the current ABR, three are Strong Buy, representing 33.33% of all recommendations. A month ago, Strong Buy represented 33.33%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 3 | 3 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 5 | 5 | 5 | 5 | 5 |
Sell | 1 | 1 | 1 | 1 | 1 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.44 | 2.44 | 2.44 | 2.44 | 2.44 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/1/2024 | William Blair | Trevor Romeo | Strong Buy | Strong Buy |
8/1/2024 | Truist Securities | Tobey O'Brien Sommer | Hold | Hold |
5/6/2024 | Barrington Research | Kevin M Steinke | Strong Buy | Strong Buy |
5/2/2024 | The Benchmark Company | William Sutherland | Strong Buy | Strong Buy |
5/2/2024 | JMP Securities | Constantine Kyriakos Davides | Hold | Hold |
5/2/2024 | Not Identified | Not Identified | Hold | Hold |
11/30/2023 | UBS | Aj Rice | Not Available | Hold |
11/4/2023 | Not Identified | Not Identified | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.44 |
ABR (Last week) | 2.44 |
# of Recs in ABR | 9 |
Average Target Price | $19.33 |
LT Growth Rate | 10.00% |
Industry | Staffing Firms |
Industry Rank by ABR | 204 of 253 |
Current Quarter EPS Est: | 0.11 |